Recro Pharma, Inc. (REPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Recro Pharma, Inc. (REPH) trades at $2.09 with AI Score 42/100 (Grade C). Recro Pharma, Inc. is a contract development and manufacturing organization specializing in small molecule therapeutic development. Market cap: $177M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 6, 2026Analyst Coverage for REPH: REPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates REPH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
REPH: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Recro Pharma, Inc. (REPH) Healthcare & Pipeline Overview
Recro Pharma, Inc. is a contract development and manufacturing organization focused on small molecule therapeutics, offering a diverse range of dosage forms and services to clients in the pharmaceutical industry, thereby enhancing its competitive edge in the healthcare sector.
What Is the Investment Thesis for REPH?
Recro Pharma, Inc. presents a compelling investment thesis driven by its unique position in the contract development and manufacturing space. The company has a market capitalization of $177M and operates with a profit margin of -14.0%, indicating potential for improvement as it scales operations. With a gross margin of 19.5%, Recro Pharma is positioned to leverage its diverse product offerings and expand its client base in the growing pharmaceutical sector. Key growth catalysts include increasing demand for specialized manufacturing services and the expansion of its product lines into new therapeutic areas. However, the company faces risks such as regulatory challenges and competitive pressures from larger firms in the industry. Investors should monitor Recro Pharma's operational efficiency and market penetration strategies as indicators of future performance.
Based on FMP financials and quantitative analysis
REPH Key Highlights
- Market Cap of $177M indicates a small but significant presence in the drug manufacturing sector.
- Profit Margin of -14.0% highlights current challenges but potential for operational improvements.
- Gross Margin of 19.5% reflects the company's ability to manage costs amid competitive pressures.
- Beta of 1.12 suggests volatility in stock performance relative to the market.
- No dividend yield indicates a focus on reinvestment for growth rather than returning capital to shareholders.
Who Are REPH's Competitors?
REPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMRI Albany Molecular Research, Inc. | $21.74 | +0.00% | 49 | |
| CAMP CAMP4 Therapeutics Corporation | $3.01 | -3.22% | $63.9M | — |
| IQV IQVIA Holdings Inc. | $204.25 | +2.89% | $35.0B | 68 |
| EMBC Embecta Corp. | $3.25 | +0.00% | $193M | 73 |
| SIGA SIGA Technologies, Inc. | $3.15 | -7.08% | $226M | 74 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| CPHRF Cipher Pharmaceuticals Inc. | $11.62 | -0.53% | $295M | 63 |
| VREOF Vireo Growth Inc. | $9.75 | -0.61% | $373M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REPH's Key Strengths?
- Strong expertise in small molecule therapeutic development.
- Diverse range of dosage forms and manufacturing capabilities.
- Established reputation for quality and reliability.
What Are REPH's Weaknesses?
- Negative profit margin indicating current operational challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on a small number of key clients for revenue.
What Could Drive REPH Stock Higher?
- Expansion of service offerings to include new therapeutic areas by Q4 2026.
- Development of partnerships with pharmaceutical companies for contract manufacturing.
- Implementation of operational improvements to enhance efficiency and reduce costs.
What Are the Key Risks for REPH?
- Financial-distress signal — its Altman Z-Score of -1.06 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-22.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes that could impact manufacturing processes.
- Competitive pressures from larger firms in the drug manufacturing sector.
- Fluctuations in demand for contract manufacturing services due to market conditions.
What Are the Growth Opportunities for REPH?
- Growth opportunity 1: The global contract manufacturing market is expected to reach $175 billion by 2026, driven by increasing outsourcing trends among pharmaceutical companies. Recro Pharma can capitalize on this growth by expanding its service offerings and enhancing its operational capabilities to meet the rising demand for specialized manufacturing services.
- Growth opportunity 2: The rise in personalized medicine is creating a demand for tailored therapeutic solutions. Recro Pharma's expertise in small molecule therapeutics positions it to develop and manufacture customized drug formulations, tapping into a market projected to grow at a CAGR of 10% over the next five years.
- Growth opportunity 3: The increasing prevalence of chronic diseases is driving the need for innovative drug delivery systems. Recro Pharma's capabilities in sterile injectables and advanced dosage forms can enable it to attract partnerships with pharmaceutical companies focused on developing next-generation therapies.
- Growth opportunity 4: Expansion into international markets presents a significant opportunity for Recro Pharma. As global healthcare spending continues to rise, the company can leverage its manufacturing expertise to establish partnerships with foreign pharmaceutical firms, enhancing its revenue streams.
- Growth opportunity 5: The trend towards sustainability in pharmaceuticals is prompting companies to seek eco-friendly manufacturing solutions. Recro Pharma can differentiate itself by adopting green manufacturing practices, appealing to environmentally conscious clients and potentially opening new market segments.
What Opportunities Does REPH Have?
- Growing demand for contract manufacturing services in pharmaceuticals.
- Expansion into international markets to diversify revenue streams.
- Increasing trend towards personalized medicine and customized therapies.
What Threats Does REPH Face?
- Intense competition from larger, established firms in the industry.
- Regulatory challenges that could impact operational efficiency.
- Market volatility and economic downturns affecting client budgets.
What Are REPH's Competitive Advantages?
- Expertise in small molecule therapeutics provides a competitive edge.
- Established reputation for quality and reliability in manufacturing.
- Diverse service offerings cater to a wide range of client needs.
- Strong relationships with clients foster loyalty and repeat business.
- Ability to adapt to changing market demands enhances resilience.
What Does REPH Do?
Founded in 2007 and based in Exton, Pennsylvania, Recro Pharma, Inc. initially operated as Recro Pharma I, Inc. before rebranding in August 2008. The company specializes in contract development and manufacturing services for various therapeutic dosage forms, primarily focusing on small molecule therapeutics. Recro Pharma offers a comprehensive suite of products, including oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles. Its capabilities extend to aseptic fill/finish, lyophilization, packaging, and logistics services, making it a versatile partner for pharmaceutical companies. With a workforce of 185 employees, Recro Pharma has positioned itself as a reliable provider in the competitive landscape of drug manufacturing. The company's strategic focus on quality and innovation has allowed it to cater to both domestic and international markets, enhancing its reputation and client base. As the healthcare industry evolves, Recro Pharma continues to adapt its offerings to meet the changing needs of its clients, ensuring it remains a relevant player in the industry.
What Products and Services Does REPH Offer?
- Develops and manufactures a wide range of therapeutic dosage forms.
- Specializes in small molecule therapeutic development.
- Offers services including aseptic fill/finish and lyophilization.
- Provides packaging and logistics services for pharmaceutical products.
- Focuses on both domestic and international markets.
- Engages in the production of oral solid doses, sterile injectables, and topicals.
How Does REPH Make Money?
- Generates revenue through contract manufacturing agreements with pharmaceutical companies.
- Offers a diverse array of dosage forms and services to meet client needs.
- Focuses on specialized manufacturing processes to differentiate from competitors.
- Engages in long-term partnerships with clients for ongoing projects.
- Utilizes a flexible operational model to adapt to changing market demands.
What Industry Does REPH Operate In?
The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing robust growth, driven by increasing healthcare demands and advancements in pharmaceutical technologies. The global contract development and manufacturing market is projected to grow significantly, fueled by the rising need for specialized services among pharmaceutical companies. Recro Pharma, Inc. operates in a competitive landscape, facing challenges from larger firms with more extensive resources. However, its focus on small molecule therapeutics and diverse service offerings positions it well to capture market share in niche segments.
Who Are REPH's Key Customers?
- Pharmaceutical companies seeking contract manufacturing services.
- Biotechnology firms developing new therapies.
- Healthcare organizations requiring specialized drug formulations.
- Research institutions needing support for clinical trials.
- International clients looking for reliable manufacturing partners.
ROE -22%Key Financial Metrics
Return on equity for Recro Pharma, Inc. stands at -22.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.7%, the inverse of the P/E and a quick read on earnings relative to price.
How Recro Pharma, Inc. Is Valued
Recro Pharma, Inc. carries a market capitalization of $177M, placing it in the micro-cap category. Relative to its peer group, REPH's quantitative score of 42/100 is below the peer average of 66/100.
F-Score 2/9Financial Health
Recro Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.06 places it in the distress zone, a signal of elevated financial risk.
REPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Recro Pharma's future, indicating that those with the most insight into the company believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to pain management and its potential market impact.
- Recent announcements regarding partnerships or collaborations have generated excitement among investors, reflecting optimism about future product developments.
- The company has been actively engaging with the investor community, fostering a sense of transparency and trust that often leads to bullish sentiment.
Bear Case
- Despite recent positive sentiment, concerns remain about the competitive landscape in the pharmaceutical industry, which could hinder Recro's market share.
- Some community members express skepticism regarding the company's ability to bring products to market effectively, citing past delays and setbacks.
- Market perception remains cautious due to broader economic uncertainties that could impact funding and investment in biotech firms like Recro Pharma.
- Recent discussions have highlighted potential regulatory hurdles that could slow down product approvals, raising doubts among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
REPH Latest News
No recent news available for REPH.
REPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REPH.
Price Targets
Wall Street price target analysis for REPH.
REPH MoonshotScore
What does this score mean?
The MoonshotScore rates REPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Geraldine Henwood
CEO
Geraldine Henwood has extensive experience in the pharmaceutical and biotechnology sectors, having held various leadership roles throughout her career. She has a strong background in operations and strategic development, which has been instrumental in guiding Recro Pharma's growth and innovation. Henwood holds a degree in Pharmaceutical Sciences and has worked with several prominent companies before joining Recro Pharma.
Track Record: Under Geraldine Henwood's leadership, Recro Pharma has expanded its service offerings and improved operational efficiencies. Her strategic vision has led to the establishment of key partnerships and an enhanced market presence.
What Investors Ask About Recro Pharma, Inc. (REPH) — Healthcare
What does the AI Score mean for REPH?
REPH holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Recro Pharma, Inc. is a contract development and manufacturing organization specializing in small molecule therapeutic development. The company provides a range of dosage forms and services …
What does Recro Pharma, Inc. do?
Recro Pharma, Inc. is a contract development and manufacturing organization that specializes in the development, manufacturing, and packaging of various therapeutic dosage forms. The company focuses on small molecule therapeutics and offers a wide range of products, including oral solid doses, sterile injectables, and advanced drug delivery systems. Recro Pharma serves both domestic and international clients, providing tailored solutions to meet the specific needs of pharmaceutical companies.
What do analysts say about REPH stock?
Analysts generally view Recro Pharma, Inc. as a company with potential for growth, particularly in the contract manufacturing sector. Key valuation metrics indicate a market capitalization of $177M, with a focus on improving operational efficiency and expanding service offerings. Analysts highlight the company's unique positioning in the small molecule therapeutic space as a positive factor, although they also note challenges related to its current negative profit margin and competitive landscape.
What are the main risks for REPH?
Recro Pharma, Inc. faces several risks that could impact its performance, including regulatory challenges that may affect its manufacturing processes and operational efficiency. Additionally, the company operates in a highly competitive environment, with larger firms posing significant threats to market share. Economic fluctuations could also lead to reduced demand for contract manufacturing services, impacting revenue. Investors may want to evaluate these factors when evaluating the company's growth potential.
What are the key factors to evaluate for REPH?
Recro Pharma, Inc. (REPH) holds an AI score of 42/100 (low). Not financial advice.
How frequently does REPH data refresh on this page?
REPH's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven REPH's recent stock price performance?
Recro Pharma, Inc. (REPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong expertise in small molecule therapeutic development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider REPH overvalued or undervalued right now?
Recro Pharma, Inc. (REPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research REPH before investing?
Before investing in Recro Pharma, Inc. (REPH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information as of May 2026.